Last 12 months
Inside the activity.
0 purchase rows · 28 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 20 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2018 Filed Dec 17, 2018 22:19 UTC |
Stone Adam LeoDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,165 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0001012975-18-001285 · edgar.xml · derivative · entry 1 Stone Adam Leo · CIK 0001727440 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,165 Underlying: Common Stock · 8,165 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:05 UTC |
Huffines Robert LutherDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 8,165 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0000899243-18-031200 · doc4.xml · derivative · entry 1 Huffines Robert Luther · CIK 0001728221 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,165 Underlying: Common Stock · 8,165 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to I 00% of the unvested portion of such option upon specified change in control events. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:46 UTC |
Koppel AdamDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 8,165 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0000899243-18-031228 · doc4.xml · derivative · entry 1 Koppel Adam · CIK 0001578965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,165 Underlying: Common Stock · 8,165 shares Expires 2028-12-13 F1 · shares: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. F1 · derivative.underlying_shares: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:12 UTC |
Sullivan Lynne MarieDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 8,165 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0000899243-18-031211 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,165 Underlying: Common Stock · 8,165 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:09 UTC |
Shah Rajeev M.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 8,165 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0000899243-18-031208 · doc4.xml · derivative · entry 1 Shah Rajeev M. · CIK 0001619841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,165 Underlying: Common Stock · 8,165 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:07 UTC |
Freed Martin IDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 16,331 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0000899243-18-031205 · doc4.xml · derivative · entry 1 Freed Martin I · CIK 0001676653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,331 Underlying: Common Stock · 16,331 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests as to one-third of the total number of shares on each of July 25, 2019, July 25, 2020, and July 25, 2021, and will vest automatically as to 100% of the unvested portion of such option upon specified chage in control events. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:05 UTC |
Arnold Matthew BennettDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 8,165 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0000899243-18-031202 · doc4.xml · derivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,165 Underlying: Common Stock · 8,165 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:05 UTC |
Amorrortu Pedro AlvaroChief Operating Officer
|
SaleCommon Stock | 300 | $32.38 | $9,714.99 |
DisclosureSEC source: 0000899243-18-030088 · doc4.xml · nonDerivative · entry 3 Amorrortu Pedro Alvaro · CIK 0001727552 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,046 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.03 to $32.56, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:05 UTC |
Amorrortu Pedro AlvaroChief Operating Officer
|
SaleCommon Stock | 5,693 | $31.44 | $178,996.46 |
DisclosureSEC source: 0000899243-18-030088 · doc4.xml · nonDerivative · entry 2 Amorrortu Pedro Alvaro · CIK 0001727552 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,346 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.04 to $31.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:05 UTC |
Amorrortu Pedro AlvaroChief Operating Officer
|
SaleCommon Stock | 3,007 | $30.20 | $90,822.83 |
DisclosureSEC source: 0000899243-18-030088 · doc4.xml · nonDerivative · entry 1 Amorrortu Pedro Alvaro · CIK 0001727552 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,039 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.94, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:01 UTC |
Quiroz Jorge ArmandoChief Medical Officer
|
SaleCommon Stock | 1,370 | $32.24 | $44,174.42 |
DisclosureSEC source: 0000899243-18-030087 · doc4.xml · nonDerivative · entry 4 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,092 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.56, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:01 UTC |
Quiroz Jorge ArmandoChief Medical Officer
|
SaleCommon Stock | 31,426 | $31.41 | $987,147.23 |
DisclosureSEC source: 0000899243-18-030087 · doc4.xml · nonDerivative · entry 3 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,462 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.01 to $31.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:01 UTC |
Quiroz Jorge ArmandoChief Medical Officer
|
SaleCommon Stock | 6,154 | $30.21 | $185,900.03 |
DisclosureSEC source: 0000899243-18-030087 · doc4.xml · nonDerivative · entry 2 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,888 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:01 UTC |
Quiroz Jorge ArmandoChief Medical Officer
|
SaleCommon Stock | 1,200 | $29.94 | $35,923.68 |
DisclosureSEC source: 0000899243-18-030087 · doc4.xml · nonDerivative · entry 1 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,042 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $29.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| December 03, 2018 Filed Jan 10, 2019 21:44 UTC Amendment |
Amorrortu Pedro AlvaroChief Operating Officer
|
SaleCommon Stock | 300 | $32.38 | $9,714.99 |
DisclosureSEC source: 0000899243-19-000971 · doc4a.xml · nonDerivative · entry 3 Amorrortu Pedro Alvaro · CIK 0001727552 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,746 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.03 to $32.56, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form. F5 · balance_after: Amendment corrects arithmetical error as to number of securities in Column 5 of Table I. Read SEC document |
| December 03, 2018 Filed Jan 10, 2019 21:44 UTC Amendment |
Amorrortu Pedro AlvaroChief Operating Officer
|
SaleCommon Stock | 5,693 | $31.44 | $178,996.46 |
DisclosureSEC source: 0000899243-19-000971 · doc4a.xml · nonDerivative · entry 2 Amorrortu Pedro Alvaro · CIK 0001727552 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,046 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.04 to $31.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. F5 · balance_after: Amendment corrects arithmetical error as to number of securities in Column 5 of Table I. Read SEC document |
| December 03, 2018 Filed Jan 10, 2019 21:44 UTC Amendment |
Amorrortu Pedro AlvaroChief Operating Officer
|
SaleCommon Stock | 3,007 | $30.20 | $90,822.83 |
DisclosureSEC source: 0000899243-19-000971 · doc4a.xml · nonDerivative · entry 1 Amorrortu Pedro Alvaro · CIK 0001727552 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,739 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.94, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. F5 · balance_after: Amendment corrects arithmetical error as to number of securities in Column 5 of Table I. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 11:32 UTC |
Quiroz Jorge ArmandoChief Medical Officer
|
SaleCommon Stock | 100 | $34.90 | $3,490.00 |
DisclosureSEC source: 0000899243-18-029425 · doc4.xml · nonDerivative · entry 1 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,242 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 11:30 UTC |
Zarur Juan AndreyDirector
|
SaleCommon Stock | 100 | $35.00 | $3,500.00 |
DisclosureSEC source: 0000899243-18-029423 · doc4.xml · nonDerivative · entry 1 Zarur Juan Andrey · CIK 0001727404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,105 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2018. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:14 UTC |
Ganot IlanDirector · CEO & President
|
SaleCommon Stock | 19,100 | $31.06 | $593,318.58 |
DisclosureSEC source: 0000899243-18-029304 · doc4.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,126 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.48, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. F5 · balance_after: Represents 1, 041,495 shares held by Mr. Ganot as an individual. Represents 60,631 shares held by Mr. Ganot and Ms. Annie Ganot as joint tenants with a right of survivorship. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:14 UTC |
Ganot IlanDirector · CEO & President
|
SaleCommon Stock | 30,900 | $30.70 | $948,614.55 |
DisclosureSEC source: 0000899243-18-029304 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,121,226 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.995, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. F4 · balance_after: Represents 1,060,595 shares held by Mr. Ganot as an individual. Represents 60,631 shares held by Mr. Ganot and Ms. Annie Ganot as joint tenants with a right of survivorship. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:11 UTC |
Schneider Joel Solomon ZevSee Remarks
|
SaleCommon Stock | 8,542 | $31.10 | $265,624.59 |
DisclosureSEC source: 0000899243-18-029302 · doc4.xml · nonDerivative · entry 2 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,656 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:11 UTC |
Schneider Joel Solomon ZevSee Remarks
|
SaleCommon Stock | 13,448 | $30.68 | $412,555.05 |
DisclosureSEC source: 0000899243-18-029302 · doc4.xml · nonDerivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,958 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:10 UTC |
Amorrortu Pedro AlvaroChief Operating Officer
|
SaleCommon Stock | 4,300 | $31.08 | $133,631.53 |
DisclosureSEC source: 0000899243-18-029300 · doc4.xml · nonDerivative · entry 2 Amorrortu Pedro Alvaro · CIK 0001727552 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,746 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:10 UTC |
Amorrortu Pedro AlvaroChief Operating Officer
|
SaleCommon Stock | 4,700 | $30.61 | $143,846.79 |
DisclosureSEC source: 0000899243-18-029300 · doc4.xml · nonDerivative · entry 1 Amorrortu Pedro Alvaro · CIK 0001727552 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,046 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| November 15, 2018 Filed Jan 10, 2019 21:45 UTC Amendment |
Schneider Joel Solomon ZevSee Remarks
|
SaleCommon Stock | 8,542 | $31.10 | $265,624.59 |
DisclosureSEC source: 0000899243-19-000973 · doc4a.xml · nonDerivative · entry 2 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,656 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. F4 · balance_after: Amendment corrects arithmetical error as to number of securities in Column 5 of Table I. Read SEC document |
| November 15, 2018 Filed Jan 10, 2019 21:45 UTC Amendment |
Schneider Joel Solomon ZevSee Remarks
|
SaleCommon Stock | 13,448 | $30.68 | $412,555.05 |
DisclosureSEC source: 0000899243-19-000973 · doc4a.xml · nonDerivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,198 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. F4 · balance_after: Amendment corrects arithmetical error as to number of securities in Column 5 of Table I. Read SEC document |
| September 12, 2018 Filed Sep 13, 2018 18:50 UTC |
Nagendran SukumarDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 2,760 | $0.00 Strike: $50.65 | $0.00 |
DisclosureSEC source: 0000899243-18-024397 · doc4.xml · derivative · entry 1 Nagendran Sukumar · CIK 0001665124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,760 Underlying: Common Stock · 2,760 shares Expires 2028-09-12 F1 · derivative.exercise_date: This option was granted on September 12, 2018 and vests as to one-third of the total number of shares on each of the next three anniversaries of the grant date. Read SEC document |
| August 22, 2018 Filed Aug 28, 2018 10:07 UTC |
Hayeem Gilad David10% owner
|
GiftCommon Stock | 35,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-046555 · tv501761_4.xml · nonDerivative · entry 1 Hayeem Gilad David · CIK 0001728113 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,948,991 Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 22:52 UTC |
Ganot IlanDirector · CEO & President
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 193,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0000899243-18-020707 · doc4.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,000 Underlying: Common Stock · 193,000 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 22:52 UTC |
Huffines Robert LutherDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 1,835 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0000899243-18-020708 · doc4.xml · derivative · entry 1 Huffines Robert Luther · CIK 0001728221 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,835 Underlying: Common Stock · 1,835 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 22:54 UTC |
Arnold Matthew BennettDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 1,835 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0000899243-18-020709 · doc4.xml · derivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,835 Underlying: Common Stock · 1,835 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 22:36 UTC |
Sullivan Lynne MarieDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 1,835 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0000899243-18-020704 · doc4.xml · derivative · entry 1 Sullivan Lynne Marie · CIK 0001727640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,835 Underlying: Common Stock · 1,835 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 22:36 UTC |
Shah Rajeev M.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 1,835 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0000899243-18-020703 · doc4.xml · derivative · entry 1 Shah Rajeev M. · CIK 0001619841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,835 Underlying: Common Stock · 1,835 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 22:35 UTC |
Freed Martin IDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 3,669 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0000899243-18-020702 · doc4.xml · derivative · entry 1 Freed Martin I · CIK 0001676653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,669 Underlying: Common Stock · 3,669 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests as to one-third of the total number of shares on each of the next three anniversaries of the grant date. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 21:38 UTC |
PERCEPTIVE ADVISORS LLCDirector · 10% owner
EDELMAN JOSEPH10% owner
|
GrantStock Option (Right to Buy) · Derivative | 1,835 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001012975-18-000939 · edgar.xml · derivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,835 Underlying: Common Stock · 1,835 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. F2 · ownership.nature: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Stone in connection with his role as a member of the Issuer's Board of Directors. Mr. Stone is the Chief Investment Officer of Perceptive Advisors, LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either party is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 21:36 UTC |
Stone Adam LeoDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,835 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001012975-18-000937 · edgar.xml · derivative · entry 1 Stone Adam Leo · CIK 0001727440 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,835 Underlying: Common Stock · 1,835 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:36 UTC |
Koppel AdamDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 1,835 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0000899243-18-020742 · doc4.xml · derivative · entry 1 Koppel Adam · CIK 0001578965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,835 Underlying: Common Stock · 1,835 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| February 14, 2018 Filed Feb 15, 2018 20:29 UTC |
Morris Carl AshleyChief Scientific Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 203,858 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0000899243-18-004343 · doc4.xml · derivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,858 Underlying: Common Stock · 203,858 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option shall vest in four equal installments beginning on February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 01:28 UTC |
Amorrortu Pedro AlvaroChief Operating Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 134,657 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0000899243-18-004342 · doc4.xml · derivative · entry 1 Amorrortu Pedro Alvaro · CIK 0001727552 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,657 Underlying: Common Stock · 134,657 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option shall vest in four equal installments beginning on February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 01:26 UTC |
Quiroz Jorge ArmandoChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 47,061 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0000899243-18-004339 · doc4.xml · derivative · entry 1 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,061 Underlying: Common Stock · 47,061 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option shall vest in four equal installments beginning on February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 01:22 UTC |
Schneider Joel Solomon ZevSee Remarks
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 105,677 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0000899243-18-004335 · doc4.xml · derivative · entry 1 Schneider Joel Solomon Zev · CIK 0001727649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,677 Underlying: Common Stock · 105,677 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option shall vest in four equal installments beginning on February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 01:22 UTC |
Ziolkowski Jennifer LynnSee Remarks
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 66,852 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0000899243-18-004334 · doc4.xml · derivative · entry 1 Ziolkowski Jennifer Lynn · CIK 0001727410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,852 Underlying: Common Stock · 66,852 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option shall vest in four equal installments beginning on February 14, 2019. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 18:05 UTC |
PERCEPTIVE ADVISORS LLCDirector · 10% owner
PERCEPTIVE LIFE SCIENCES MASTER FUND LTDDirector · 10% owner
EDELMAN JOSEPH10% owner
|
PurchaseCommon Stock | 20,000 | $27.33 | $546,520.00 |
DisclosureSEC source: 0001012975-18-000098 · edgar.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,927,222 F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 18:05 UTC |
PERCEPTIVE ADVISORS LLCDirector · 10% owner
PERCEPTIVE LIFE SCIENCES MASTER FUND LTDDirector · 10% owner
EDELMAN JOSEPH10% owner
|
PurchaseCommon Stock | 1,000,000 | $16.00 | $16,000,000.00 |
DisclosureSEC source: 0001012975-18-000098 · edgar.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,907,222 F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 22:43 UTC |
Shah Rajeev M.Director
|
PurchaseCommon Stock | 1,000,000 | $16.00 | $16,000,000.00 |
DisclosureSEC source: 0001144204-18-004705 · tv484454_4.xml · nonDerivative · entry 1 Shah Rajeev M. · CIK 0001619841 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,689,444 F1 · shares: These securities include 808,990 shares held by RA Capital Healthcare Fund, L.P. (the "Fund") and 191,010 shares held in an account owned by a separately managed account (the "Account"). F2 · ownership.nature: Represents 2,177,971 shares of Common Stock held by the Fund and 511,473 shares of Common Stock held in the Account. F3 · ownership.nature: RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Account. Mr. Shah is a member of the Adviser. Mr. Shah has no pecuniary interest in the reported securities held in the Account and therefore disclaims beneficial ownership of those securities. Mr. Shah disclaims beneficial ownership of the reported securities held by the Fund except to the extent of his pecuniary interest therein. Read SEC document |
| January 30, 2018 Filed Feb 2, 2018 00:07 UTC |
Koppel AdamDirector
|
PurchaseCommon Stock | 300,000 | $16.00 | $4,800,000.00 |
DisclosureSEC source: 0000899243-18-002535 · doc4.xml · nonDerivative · entry 2 Koppel Adam · CIK 0001578965 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,989,444 F4 · shares: Represents shares purchased in the Issuer's initial public offering. F3 · balance_after: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F1 · ownership.nature: Represents shares held directly by BCLS SB Investco, LP ("BCLS"). F2 · ownership.nature: The governance, investment strategy and decision-making process with respect to investments held by BCLS is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 25, 2018 Filed Feb 2, 2018 00:07 UTC |
Koppel AdamDirector
|
Exercise / conversionLLC Units · Derivative | 1,991,097 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002535 · doc4.xml · derivative · entry 4 Koppel Adam · CIK 0001578965 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,689,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · shares: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · price: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · derivative.exercise_date: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · derivative.expiration_date: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · derivative.underlying_shares: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · balance_after: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F1 · ownership.nature: Represents shares held directly by BCLS SB Investco, LP ("BCLS"). F2 · ownership.nature: The governance, investment strategy and decision-making process with respect to investments held by BCLS is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 25, 2018 Filed Feb 2, 2018 00:07 UTC |
Koppel AdamDirector
|
Exercise / conversionCommon Stock | 1,689,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002535 · doc4.xml · nonDerivative · entry 1 Koppel Adam · CIK 0001578965 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,689,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · shares: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · price: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · balance_after: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F1 · ownership.nature: Represents shares held directly by BCLS SB Investco, LP ("BCLS"). F2 · ownership.nature: The governance, investment strategy and decision-making process with respect to investments held by BCLS is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 26, 2017 Filed Feb 2, 2018 00:07 UTC |
Koppel AdamDirector
|
GrantLLC Units · Derivative | 1,223,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002535 · doc4.xml · derivative · entry 3 Koppel Adam · CIK 0001578965 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 1,991,097 Underlying: Common Stock · 1,037,919 shares Expires not disclosed F3 · derivative.exercise_price: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · shares: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · price: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · derivative.exercise_date: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · derivative.expiration_date: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · derivative.underlying_shares: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F3 · balance_after: In connection with the Issuer's initial public offering, immediately prior to the effectiveness of the Issuer's Registration Statement on Form S-1 relating thereto, the Issuer, which was previously organized as a limited liability company, converted to a corporation (the "Corporate Conversion"). Prior to the Corporate Conversion, BCLS held 1,991,097 LLC Units of the Issuer, including 112,770 Series C Common Units acquired for a total purchase price of $1,249,999.07 and 1,110,470 Series 2 Preferred Units acquired for a total purchase price of $ 12,500,560.97, in each case on October 26, 2017. In connection with the Corporate Conversion, all outstanding units of the Issuer were converted into shares of Common Stock on a one-for-0.8485 basis in an exempt transaction pursuant to Rule 16b-7. As a result, following the Corporate Conversion, BCLS held 1,689,444 shares of Common Stock. F1 · ownership.nature: Represents shares held directly by BCLS SB Investco, LP ("BCLS"). F2 · ownership.nature: The governance, investment strategy and decision-making process with respect to investments held by BCLS is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.